title: Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
abstract: Enzyme replacement therapies for lysosomal storage disorders are often hindered by suboptimal biodistribution of recombinant enzymes after systemic injection. This is the case for Pompe disease caused by acid α-glucosidase (GAA) deficiency, leading to excess glycogen storage throughout the body, mainly the liver and striated muscle. Targeting intercellular adhesion molecule-1 (ICAM-1), a protein involved in inflammation and overexpressed on most cells under pathological conditions, provides broad biodistribution and lysosomal transport of therapeutic cargoes. To improve its delivery, we coupled GAA to polymer nanocarriers (NCs; ∼180 nm) coated with an antibody specific to ICAM-1. Fluorescence microscopy showed specific targeting of anti-ICAM/GAA NCs to cells, with efficient internalization and lysosomal transport, enhancing glycogen degradation over nontargeted GAA. Radioisotope tracing in mice demonstrated enhanced GAA accumulation in all organs, including Pompe targets. Along with improved delivery of Niemann-Pick and Fabry enzymes, previously described, these results indicate that ICAM-1 targeting holds promise as a broad platform for lysosomal enzyme delivery.
  
  
  BACKGROUND
  In this study, ICAM-1 targeted nanocarriers were used to deliver GAA (acid alpha glucosidase) into cells to address the specific enzyme deficiency in Pompe's disease. The results unequivocally demonstrate enhanced enzyme delivery over nontargeted GAA in a mice model.
authors: Fischell Department of Bioengineering, School of Engineering, University of Maryland, College Park, Maryland, USA.
authors: Janet
authors: J
authors: Hsu
authors: Laura
authors: L
authors: Northrup
authors: Tridib
authors: T
authors: Bhowmick
authors: Silvia
authors: S
authors: Muro
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000737:chemistry; D004187:Disaccharides / Q000494:pharmacology; D004337:Drug Carriers / Q000737:chemistry; D056947:Enzyme Replacement Therapy; D006003:Glycogen / Q000378:metabolism; D006009:Glycogen Storage Disease Type II / Q000139:chemically induced / Q000628:therapy*; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology*; D016464:Lysosomal Storage Diseases / Q000628:therapy; D008247:Lysosomes / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D058990:Molecular Targeted Therapy; D018482:Muscle, Skeletal / Q000166:cytology; D053758:Nanoparticles / Q000737:chemistry; D011108:Polymers / Q000737:chemistry; D012441:Saccharomyces cerevisiae / Q000201:enzymology; D014018:Tissue Distribution; D000520:alpha-Glucosidases / Q000008:administration & dosage* / Q000737:chemistry*
chemical_list: D000911:Antibodies, Monoclonal; D004187:Disaccharides; D004337:Drug Carriers; D011108:Polymers; D018799:Intercellular Adhesion Molecule-1; C029454:turanose; D006003:Glycogen; D000520:alpha-Glucosidases